TABLE 3.
Summary of CF patients with pulmonary infection due to LRSA isolates and treated with LZD from 2000 to 2006a
| Characteristic | Patient 1 (strain NA) | Patient 2 (strain M36) | Patient 3 (strain I32) | Patient 4 (strain NA) | Patient 5b (strain M41) | Patient 6b (strain M94) | Patient 7 (strain M86) | Patient 8 (strain NA) |
|---|---|---|---|---|---|---|---|---|
| Age (yr)c | 3 (F) | 7 (M) | 14 (F) | 33 (M) | 10 (M) | 11 (F) | 13 (M) | 14 (F) |
| Mo/yr of first dose of LZD | 12/2002 | 7/2000 | 12/2001 | 12/2000 | 9/2000 | 2/2001 | 12/2002 | 7/2000 |
| Mo/yr when last LSSA isolate detected before occurrence of LRSA | 3/2003 | 1/2004 | Never | 4/2005 | 2/2004 | 11/2003 | 7/2005 | 4/2005 |
| Mo/yr when first LRSA isolate detected | 10/2004 | 7/2004 | 12/2004 | 6/2005 | 2/2005 | 12/2005 | 12/2006 | 8/2006 |
| Time between first dose of LZD and first LRSA isolate detected (mo) | 22 | 48 | 35 | 54 | 53 | 58 | 48 | 73 |
| No. of days of LZD use per yr/no. of treatments (dose, time)d | ||||||||
| 2000 | 0/0 | 32/1 (9 mg/kg, q12h) | 0/0 | 10/1e (600 mg, q12h) | 35/2 (4 mg/kg, q12h) | 0/0 | 0/0 | 14/1 (600 mg, q12h) |
| 2001 | 0/0 | 121/7 (10 mg/kg, q12h) | 1/1 (600 mg, q12h) | 120/0e (600 mg, q12h) | 70/4 (4 mg/kg, q12h) | 63/4 (4 mg/kg, q12h) | 0/0 | 33/2 (600 mg, q12h) |
| 2002 | 23/1 (9 mg/kg, q12h) | 165/11 (11 mg/kg, q12h) | 176/17 (600 mg, q12h) | 40/0e (600 mg, q12h) | 70/2 (10 mg/kg, q12h) | 0/0 | 15/1 (600 mg, q12h) | 69/3 (600 mg, q12h) |
| 2003 | 365/0 (9 mg/kg, q12h) | 224/4 (9 mg/kg, q12h) | 211/20 (600 mg, q12h) | 0/0 | 185/2 (10 mg/kg, q12h) | 21/1 (600 mg, q12h) | 28/2 (600 mg, q12h) | 144/5 (600 mg, q12h) |
| 2004 | 309/1 (9 mg/kg, q12h) | 44/4 (9 mg/kg, q12h) | 116/8 (600 mg, q12h) | 100/2 (600 mg, q12h) | 117/5 (7 mg/kg, q12h) | 99/2 (600 mg, q12h) | 32/2 (600 mg, q12h) | 14/1 (600 mg, q12h) |
| 2005 | 53/1 (10 mg/kg, q12h) | 56/2 (600 mg, q12h) | 0/0 | 28/2 (600 mg, q12h) | 114/5 (9 mg/kg, q12h) | 195/4 (600 mg, q12h) | 89/3 (600 mg, q12h) | 29/1 (600 mg, q12h) |
| 2006 | 268/1 (9 mg/kg, q12h) | 71/2 (600 mg, q12h) | 0/0 | 0/0 | 77/3 (600 mg, q12h) | 0/0 | 199/7 (600 mg, q12h) | 127/3 (600 mg, q12h) |
| Anti-Staphylococcus therapy given after first LRSA-positive culture | TMP-SXT, DOX, VAN | TMP-SXT, DOX, VAN | MEM, CLIN | TMP-SXT, CAZ, VAN | TMP-SXT, DOX | TMP-SXT, DOX | None | None |
| Outcomef | Alive | Alive | Deceased in 2006 | Lung transplant in 2006 | Alive | Alive | Alive | Lung transplant in 2006 |
NA, not available for molecular characterization; TMP-SXT, trimethoprim-sulfamethoxazole; DOX, doxycycline; VAN, vancomycin; CLIN, clindamycin; MEM, meropenem; CAZ, ceftazidime; M, male; F, female; q12h, every 12 h.
Patients 5 and 6 are siblings.
Age at the midpoint of the year 2000. The patient sex is given in parentheses.
For years with treatment days but zero treatments, the course was continued from the previous year. All linezolid treatments were administered orally. If more than one treatment regimen was used, then the average dose for the year is given.
Dosed the first 10 days of each month from December 2000 to April 2002.
On 31 December 2006.